Document Detail

Onset of action of etanercept in rheumatoid arthritis based on patient-peported outcomes.
MedLine Citation:
PMID:  22325048     Owner:  NLM     Status:  Publisher    
BACKGROUND: Onset of action is considered to be a key characteristic of the treatment of rheumatoid arthritis. The efficacy of TNF blockers is usually evaluated after 2 to 4 weeks of therapy. EULAR-RAID is a valid patient-reported outcome composite index. OBJECTIVES: To evaluate the onset of action of etanercept in rheumatoid arthritis patients according to the EULAR-RAID score. METHODS: An open-label, single-arm (etanercept 50 mg/week), 12-week study was carried out in patients with active rheumatoid arthritis. Patients were asked to fill in the RAID score questionnaire each day for the first 14 days of the study and at the 4-week and 12-week visits. Onset of action was evaluated by considering: a) changes over time of the EULAR-RAID score; b) the percentage of patients achieving an 'acceptable' condition according to the EULAR-RAID score (e.g. a score ≤3.00). RESULTS: Of the 120 screened patients, 108 (female: 75%), age 54±13 years, disease duration 8±7 years) were enrolled. At baseline, patients had active rheumatoid arthritis (DAS: 5.4±0.8; CRP: 18.±30mg/l). Eleven patients dropped out of the study. A statistically significant decrease in the EULAR-RAID score was observed by day 1 of therapy. Kaplan-Meier estimates of the proportion of patients achieving an acceptable RAID score were 29.8 [% 95% C.I. 23.8-X42.6], 50 % [95% C.I. 41-60.9], 51.9% [95% C.I. 43.8-63.7], 56% [95% C.I. 49.5-69.1, after 1, 2, 4 and 12 weeks of therapy respectively. The median time to achieve an acceptable EULAR-RAID score was 14.5 days. CONCLUSIONS: This open-label study suggests that patients can perceive a clinically relevant improvement by the first week of etanercept therapy.
Maxime Dougados; Mahaut Ripert; Pascal Hilliquin; Olivier Brocq; Yves Brault; Isabelle Logeart
Related Documents :
22727318 - A new risk classification rule for curve progression in adolescent idiopathic scoliosis.
15692238 - Management of patients with acute venous thromboembolism: findings from the riete regis...
22856598 - Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomp...
19919878 - Efficacy and safety of enoxaparin in japanese patients undergoing curative abdominal or...
12352408 - A critical analysis of the interpretation of biochemical failure in surgically treated ...
7858048 - Late results of anterior sphincter plication for traumatic faecal incontinence.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-8
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  -     ISSN:  0392-856X     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Paris-Descartes University; UPRES EA 4058; APHP, Cochin Hospital, Rheumatology B Dpt, 75014 Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A common variant associated with asthma, interleukin 13 R130Q, promotes the production of IgE.
Next Document:  Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review.